122 related articles for article (PubMed ID: 7733839)
1. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study.
Trouillas P; Serratrice G; Laplane D; Rascol A; Augustin P; Barroche G; Clanet M; Degos CF; Desnuelle C; Dumas R
Arch Neurol; 1995 May; 52(5):456-60. PubMed ID: 7733839
[TBL] [Abstract][Full Text] [Related]
2. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases.
Wessel K; Hermsdörfer J; Deger K; Herzog T; Huss GP; Kömpf D; Mai N; Schimrigk K; Wittkämper A; Ziegler W
Arch Neurol; 1995 May; 52(5):451-5. PubMed ID: 7733838
[TBL] [Abstract][Full Text] [Related]
3. A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia.
Filla A; De Michele G; Orefice G; Santorelli F; Trombetta L; Banfi S; Squitieri F; Napolitano G; Puma D; Campanella G
Can J Neurol Sci; 1993 Feb; 20(1):52-5. PubMed ID: 8467430
[TBL] [Abstract][Full Text] [Related]
4. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing.
Trouillas P; Brudon F; Adeleine P
Arch Neurol; 1988 Nov; 45(11):1217-22. PubMed ID: 3190503
[TBL] [Abstract][Full Text] [Related]
5. [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
Trouillas P; Garde A; Robert JM; Adeleine P
C R Seances Acad Sci III; 1981 Jan; 292(1):119-22. PubMed ID: 6786764
[TBL] [Abstract][Full Text] [Related]
6. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.
Romano S; Coarelli G; Marcotulli C; Leonardi L; Piccolo F; Spadaro M; Frontali M; Ferraldeschi M; Vulpiani MC; Ponzelli F; Salvetti M; Orzi F; Petrucci A; Vanacore N; Casali C; Ristori G
Lancet Neurol; 2015 Oct; 14(10):985-91. PubMed ID: 26321318
[TBL] [Abstract][Full Text] [Related]
7. Friedreich's ataxia: idebenone treatment in early stage patients.
Artuch R; Aracil A; Mas A; Colomé C; Rissech M; Monrós E; Pineda M
Neuropediatrics; 2002 Aug; 33(4):190-3. PubMed ID: 12368988
[TBL] [Abstract][Full Text] [Related]
8. Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.
Zesiewicz T; Heerinckx F; De Jager R; Omidvar O; Kilpatrick M; Shaw J; Shchepinov MS
Mov Disord; 2018 Jul; 33(6):1000-1005. PubMed ID: 29624723
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.
Zesiewicz T; Salemi JL; Perlman S; Sullivan KL; Shaw JD; Huang Y; Isaacs C; Gooch C; Lynch DR; Klein MB
Neurodegener Dis Manag; 2018 Aug; 8(4):233-242. PubMed ID: 30051753
[TBL] [Abstract][Full Text] [Related]
10. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.
Trouillas P; Xie J; Adeleine P; Michel D; Vighetto A; Honnorat J; Dumas R; Nighoghossian N; Laurent B
Arch Neurol; 1997 Jun; 54(6):749-52. PubMed ID: 9193210
[TBL] [Abstract][Full Text] [Related]
11. Functional and Gait Assessment in Children and Adolescents Affected by Friedreich's Ataxia: A One-Year Longitudinal Study.
Vasco G; Gazzellini S; Petrarca M; Lispi ML; Pisano A; Zazza M; Della Bella G; Castelli E; Bertini E
PLoS One; 2016; 11(9):e0162463. PubMed ID: 27598307
[TBL] [Abstract][Full Text] [Related]
12. Application of a Scale for the Assessment and Rating of Ataxia (SARA) in Friedreich's ataxia patients according to posturography is limited.
Schwabova J; Maly T; Laczo J; Zumrova A; Komarek V; Musova Z; Zahalka F
J Neurol Sci; 2014 Jun; 341(1-2):64-7. PubMed ID: 24768059
[TBL] [Abstract][Full Text] [Related]
13. Friedreich's ataxia and scoliosis: the experience at two institutions.
Milbrandt TA; Kunes JR; Karol LA
J Pediatr Orthop; 2008 Mar; 28(2):234-8. PubMed ID: 18388721
[TBL] [Abstract][Full Text] [Related]
14. Friedreich's ataxia. Revision of the phenotype according to molecular genetics.
Schöls L; Amoiridis G; Przuntek H; Frank G; Epplen JT; Epplen C
Brain; 1997 Dec; 120 ( Pt 12)():2131-40. PubMed ID: 9448568
[TBL] [Abstract][Full Text] [Related]
15. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study.
Meier T; Perlman SL; Rummey C; Coppard NJ; Lynch DR
J Neurol; 2012 Feb; 259(2):284-91. PubMed ID: 21779958
[TBL] [Abstract][Full Text] [Related]
16. Can rehabilitation improve the health and well-being in Friedreich's ataxia: a randomized controlled trial?
Milne SC; Corben LA; Roberts M; Murphy A; Tai G; Georgiou-Karistianis N; Yiu EM; Delatycki MB
Clin Rehabil; 2018 May; 32(5):630-643. PubMed ID: 29072092
[TBL] [Abstract][Full Text] [Related]
17. A controlled study of oral vigabatrin (gamma-vinyl GABA) in patients with cerebellar ataxia.
Bonnet AM; Esteguy M; Tell G; Schechter PJ; Hardenberg J; Agid Y
Can J Neurol Sci; 1986 Nov; 13(4):331-3. PubMed ID: 3465425
[TBL] [Abstract][Full Text] [Related]
18. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis.
Monaca-Charley C; Stojkovic T; Duhamel A; De Seze J; Ferriby D; Vermersch P
J Neurol; 2003 Oct; 250(10):1190-4. PubMed ID: 14586600
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in Friedreich's ataxia after withdrawal from idebenone.
Cook A; Boesch S; Heck S; Brunt E; Klockgether T; Schöls L; Schulz A; Giunti P
Acta Neurol Scand; 2019 Jun; 139(6):533-539. PubMed ID: 30887496
[TBL] [Abstract][Full Text] [Related]
20. Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
Trouillas P
Ital J Neurol Sci; 1984 Sep; 5(3):253-66. PubMed ID: 6334064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
